Antiasthmatic Drugs Targeting the Cysteinyl Leukotriene Receptor 1 Alleviate Central Nervous System Inflammatory Cell Infiltration and Pathogenesis of Experimental Autoimmune Encephalomyelitis
文献类型：期刊论文
| 作者 | Wang, Liefeng1; Du, Changsheng1; Lv, Jie1; Wei, Wei1; Cui, Ye1; Xie, Xin1,2
|
| 刊名 | JOURNAL OF IMMUNOLOGY
 |
| 出版日期 | 2011-09-01 |
| 卷号 | 187期号:5页码:2336-2345 |
| ISSN号 | 0022-1767 |
| DOI | 10.4049/jimmunol.1100333 |
| 文献子类 | Article |
| 英文摘要 | Cysteinyl leukotrienes (CysLTs) are potent proinflammatory mediators and are considered to play a key role in inflammatory diseases such as asthma. Antagonists targeting the receptor of CysLTs (CysLT1) are currently used as antiasthmatic drugs. CysLTs have also been implicated in other inflammatory reactions. In this study, we report that in experimental autoimmune encephalomyelitis animals, CysLT1 is upregulated in immune tissue and the spinal cord, and CysLT levels in the blood and cerebrospinal fluid are also higher than in normal mice. Two clinically used antiasthma drugs, montelukast and zafirlukast, both targeting CysLT1, effectively block the CNS infiltration of inflammatory cells and thus reduce the incidence, peak severity, and cumulative clinical scores. Further study indicated that CysLT1 signaling does not affect the differentiation of pathogenic T helper cells. It might affect the pathogenesis of experimental autoimmune encephalomyelitis by increasing the secretion of IL-17 from myelin oligodendrocyte glycoprotein-specific T cells, increasing the permeability of the blood-brain barrier and inducing chemotaxis of T cells. These effects can be blocked by CysLT1 antagonists. Our findings indicate that the antiasthmatic drugs against CysLT1 can also be used to treat multiple sclerosis. The Journal of Immunology, 2011, 187: 2336-2345. |
| WOS关键词 | BLOOD-BRAIN-BARRIER ; PROTEIN-COUPLED RECEPTORS ; TIGHT JUNCTION PROTEINS ; MULTIPLE-SCLEROSIS ; VASCULAR-PERMEABILITY ; GENE-EXPRESSION ; MURINE MODEL ; MOUSE MODEL ; MAST-CELLS ; DISEASE |
| 资助项目 | National Natural Science Foundation of China[31000399] ; National Natural Science Foundation of China[90713047] ; Ministry of Science and Technology of China[2008DFB30150] ; Ministry of Science and Technology of China[2009ZX09302-001] ; Shanghai Commission of Science and Technology[08431910100] ; Shanghai Commission of Science and Technology[09DZ2260100] ; National Basic Research Program of China (973 Program)[2011CB965104] ; Roche RD Center China[00000000] |
| WOS研究方向 | Immunology |
| 语种 | 英语 |
| WOS记录号 | WOS:000294059500038 |
| 出版者 | AMER ASSOC IMMUNOLOGISTS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/278426]  |
| 专题 | 国家新药筛选中心 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Xie, Xin |
| 作者单位 | 1.Tongji Univ, Shanghai Key Lab Signaling & Dis Res, Sch Life Sci & Technol, Shanghai 200092, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Liefeng,Du, Changsheng,Lv, Jie,et al. Antiasthmatic Drugs Targeting the Cysteinyl Leukotriene Receptor 1 Alleviate Central Nervous System Inflammatory Cell Infiltration and Pathogenesis of Experimental Autoimmune Encephalomyelitis[J]. JOURNAL OF IMMUNOLOGY,2011,187(5):2336-2345. |
| APA | Wang, Liefeng,Du, Changsheng,Lv, Jie,Wei, Wei,Cui, Ye,&Xie, Xin.(2011).Antiasthmatic Drugs Targeting the Cysteinyl Leukotriene Receptor 1 Alleviate Central Nervous System Inflammatory Cell Infiltration and Pathogenesis of Experimental Autoimmune Encephalomyelitis.JOURNAL OF IMMUNOLOGY,187(5),2336-2345. |
| MLA | Wang, Liefeng,et al."Antiasthmatic Drugs Targeting the Cysteinyl Leukotriene Receptor 1 Alleviate Central Nervous System Inflammatory Cell Infiltration and Pathogenesis of Experimental Autoimmune Encephalomyelitis".JOURNAL OF IMMUNOLOGY 187.5(2011):2336-2345. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。